Quoin Pharmaceuticals Advances FDA Approval Process for QRX003
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy QNRX?
Source: Newsfilter
- FDA Approval for New Study Design: The FDA indicated that a single Phase 3 study may suffice for QRX003's U.S. marketing approval, significantly reducing Quoin's original requirement for two studies, thereby accelerating the product's path to market.
- Innovative Clinical Trial Design: The FDA expressed openness to alternative trial designs such as randomized withdrawal or delayed start, which may be more suitable for treating Netherton Syndrome, enhancing Quoin's flexibility and adaptability in clinical trials.
- Patient Recruitment Timeline: Quoin aims to complete patient recruitment for its Phase 3 study by the end of 2026 and potentially file for FDA approval in 2027, which, if successful, would make it the first approved treatment for Netherton Syndrome, addressing a critical market need.
- Clinical Data Submission: The company plans to submit clinical data from ongoing Phase 2 and pediatric studies based on FDA feedback and intends to meet with the FDA before initiating the pivotal Phase 3 program to ensure alignment on the study design.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QNRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QNRX
Wall Street analysts forecast QNRX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.410
Low
70.00
Averages
70.00
High
70.00
Current: 6.410
Low
70.00
Averages
70.00
High
70.00
About QNRX
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Quoin Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Surprise: Quoin Pharmaceuticals reported a Q4 GAAP EPS of -$1.74, beating expectations by $2.28, indicating an improvement in financial performance despite still being in a loss position.
- Strong Cash Reserves: As of December 31, 2025, Quoin had approximately $18.7 million in cash, cash equivalents, and marketable securities, providing a solid financial cushion for future operations.
- Operational Funding Outlook: The company believes its year-end cash position will sustain operations into 2027, reflecting a prudent approach to cash management that supports long-term growth.
- Increased Market Attention: Following the earnings release, Quoin Pharmaceuticals has garnered heightened market interest, with investors showing greater curiosity about its future profitability and cash flow management.
See More
Quoin Pharmaceuticals Provides Clinical Update on QRX003
- FDA Meeting Outcome: Quoin Pharmaceuticals learned during its Type C meeting with the FDA that a single Phase 3 study may suffice for U.S. marketing approval of QRX003 for Netherton Syndrome, significantly reducing the clinical burden compared to the initially contemplated two studies, potentially accelerating the product's market entry.
- Flexibility in Trial Design: The FDA expressed openness to alternative clinical trial designs, such as randomized withdrawal or randomized delayed start, which provides Quoin with greater flexibility in designing the pivotal Phase 3 study, aiding in optimizing the study protocol to meet regulatory requirements.
- Stock Price Volatility Ahead of Earnings: Quoin's stock price fell 6.36% to $8.68 in pre-market trading, reflecting market caution ahead of its upcoming fourth-quarter and full-year 2025 financial results, which may impact investor sentiment and future stock performance.
- Diverse Product Pipeline: Quoin's pipeline includes candidates targeting various rare diseases, with QRX003 also being explored for Peeling Skin Syndrome and other conditions, showcasing the company's broad positioning in the rare disease sector and potential market opportunities.
See More
Quoin Pharmaceuticals Shares Surge 20% on FDA Feedback for QRX003
- Positive FDA Feedback: Quoin Pharmaceuticals received encouraging news from the FDA regarding its lead drug QRX003 for treating Netherton Syndrome, indicating that a single Phase 3 trial may suffice for U.S. approval, leading to a more than 20% surge in pre-market trading.
- Trial Design Flexibility: The FDA also expressed openness to alternative trial designs that may not require a traditional placebo group, providing Quoin with greater flexibility in its clinical trials and potentially reducing development risks.
- Advancing Phase 3 Plans: Following the positive feedback from the FDA, Quoin plans to advance its Phase 3 clinical trial program and aims to file for approval as early as 2027, demonstrating the company's confidence and commitment to addressing Netherton Syndrome.
- Clinical Network Advantage: CEO Michael Myers stated that with their established network of U.S. and EU clinical trial sites, Quoin is confident in initiating its pivotal Phase 3 program and completing patient enrollment this year, further solidifying its market position.
See More
QNRX Shares Jump 20% in Pre-Market Trading – FDA's Comments on Netherton Syndrome Treatment?
Stock Surge: Shares of Quoin Pharmaceuticals (QNRX) increased by over 20% in pre-market trading following positive feedback from the FDA regarding its lead drug QRX003 for treating Netherton syndrome.
FDA Trial Insights: The FDA indicated that a single Phase 3 trial may suffice for U.S. approval, which is a departure from the usual requirement of two studies, and showed openness to alternative trial designs.
Future Plans: Quoin Pharmaceuticals plans to advance its Phase 3 program and is on track to complete patient enrollment this year, with potential for filing for approval as early as 2027.
CEO's Confidence: CEO Michael Myers expressed confidence in the company's established network of clinical trial sites in the U.S. and EU, indicating readiness to initiate the pivotal Phase 3 program.
See More
Quoin Pharmaceuticals Advances FDA Approval Process for QRX003
- FDA Approval for New Study Design: The FDA indicated that a single Phase 3 study may suffice for QRX003's U.S. marketing approval, significantly reducing Quoin's original requirement for two studies, thereby accelerating the product's path to market.
- Innovative Clinical Trial Design: The FDA expressed openness to alternative trial designs such as randomized withdrawal or delayed start, which may be more suitable for treating Netherton Syndrome, enhancing Quoin's flexibility and adaptability in clinical trials.
- Patient Recruitment Timeline: Quoin aims to complete patient recruitment for its Phase 3 study by the end of 2026 and potentially file for FDA approval in 2027, which, if successful, would make it the first approved treatment for Netherton Syndrome, addressing a critical market need.
- Clinical Data Submission: The company plans to submit clinical data from ongoing Phase 2 and pediatric studies based on FDA feedback and intends to meet with the FDA before initiating the pivotal Phase 3 program to ensure alignment on the study design.
See More
Biotech Landscape Update: Regulatory Approvals and Mergers
- Anavex Drug Withdrawal: Anavex Life Sciences Corp. (AVXL) withdrew its EU marketing application for Alzheimer's drug Blarcamesine after the EMA's CHMP indicated it could not issue a positive opinion, marking a significant setback for the company's lead candidate despite continued support from patient groups.
- Quoin FDA Alignment: Quoin Pharmaceuticals Ltd. (QNRX) received positive feedback from the FDA confirming that a single Phase 3 trial may suffice for U.S. approval of QRX003 for Netherton Syndrome, with plans to initiate Phase 3 in 2026 and potentially file an NDA in 2027.
- Corcept Drug Approval: Corcept Therapeutics Inc. (CORT) secured FDA approval for Lifyorli combined with nab-paclitaxel to treat platinum-resistant ovarian cancer, based on Phase 3 ROSELLA trial results involving 381 patients, marking the first FDA-approved selective glucocorticoid receptor antagonist.
- Merck Acquires Terns: Merck (MRK) announced a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share, totaling approximately $6.7 billion, which is expected to enhance Merck's presence in hematology, with the transaction anticipated to close in Q2 2026.
See More
Quoin Pharmaceuticals Q4 Earnings Beat Expectations
- Earnings Surprise: Quoin Pharmaceuticals reported a Q4 GAAP EPS of -$1.74, beating expectations by $2.28, indicating an improvement in financial performance despite still being in a loss position.
- Strong Cash Reserves: As of December 31, 2025, Quoin had approximately $18.7 million in cash, cash equivalents, and marketable securities, providing a solid financial cushion for future operations.
- Operational Funding Outlook: The company believes its year-end cash position will sustain operations into 2027, reflecting a prudent approach to cash management that supports long-term growth.
- Increased Market Attention: Following the earnings release, Quoin Pharmaceuticals has garnered heightened market interest, with investors showing greater curiosity about its future profitability and cash flow management.
See More
Quoin Pharmaceuticals Provides Clinical Update on QRX003
- FDA Meeting Outcome: Quoin Pharmaceuticals learned during its Type C meeting with the FDA that a single Phase 3 study may suffice for U.S. marketing approval of QRX003 for Netherton Syndrome, significantly reducing the clinical burden compared to the initially contemplated two studies, potentially accelerating the product's market entry.
- Flexibility in Trial Design: The FDA expressed openness to alternative clinical trial designs, such as randomized withdrawal or randomized delayed start, which provides Quoin with greater flexibility in designing the pivotal Phase 3 study, aiding in optimizing the study protocol to meet regulatory requirements.
- Stock Price Volatility Ahead of Earnings: Quoin's stock price fell 6.36% to $8.68 in pre-market trading, reflecting market caution ahead of its upcoming fourth-quarter and full-year 2025 financial results, which may impact investor sentiment and future stock performance.
- Diverse Product Pipeline: Quoin's pipeline includes candidates targeting various rare diseases, with QRX003 also being explored for Peeling Skin Syndrome and other conditions, showcasing the company's broad positioning in the rare disease sector and potential market opportunities.
See More
Quoin Pharmaceuticals Shares Surge 20% on FDA Feedback for QRX003
- Positive FDA Feedback: Quoin Pharmaceuticals received encouraging news from the FDA regarding its lead drug QRX003 for treating Netherton Syndrome, indicating that a single Phase 3 trial may suffice for U.S. approval, leading to a more than 20% surge in pre-market trading.
- Trial Design Flexibility: The FDA also expressed openness to alternative trial designs that may not require a traditional placebo group, providing Quoin with greater flexibility in its clinical trials and potentially reducing development risks.
- Advancing Phase 3 Plans: Following the positive feedback from the FDA, Quoin plans to advance its Phase 3 clinical trial program and aims to file for approval as early as 2027, demonstrating the company's confidence and commitment to addressing Netherton Syndrome.
- Clinical Network Advantage: CEO Michael Myers stated that with their established network of U.S. and EU clinical trial sites, Quoin is confident in initiating its pivotal Phase 3 program and completing patient enrollment this year, further solidifying its market position.
See More
QNRX Shares Jump 20% in Pre-Market Trading – FDA's Comments on Netherton Syndrome Treatment?
Stock Surge: Shares of Quoin Pharmaceuticals (QNRX) increased by over 20% in pre-market trading following positive feedback from the FDA regarding its lead drug QRX003 for treating Netherton syndrome.
FDA Trial Insights: The FDA indicated that a single Phase 3 trial may suffice for U.S. approval, which is a departure from the usual requirement of two studies, and showed openness to alternative trial designs.
Future Plans: Quoin Pharmaceuticals plans to advance its Phase 3 program and is on track to complete patient enrollment this year, with potential for filing for approval as early as 2027.
CEO's Confidence: CEO Michael Myers expressed confidence in the company's established network of clinical trial sites in the U.S. and EU, indicating readiness to initiate the pivotal Phase 3 program.
See More
Quoin Pharmaceuticals Advances FDA Approval Process for QRX003
- FDA Approval for New Study Design: The FDA indicated that a single Phase 3 study may suffice for QRX003's U.S. marketing approval, significantly reducing Quoin's original requirement for two studies, thereby accelerating the product's path to market.
- Innovative Clinical Trial Design: The FDA expressed openness to alternative trial designs such as randomized withdrawal or delayed start, which may be more suitable for treating Netherton Syndrome, enhancing Quoin's flexibility and adaptability in clinical trials.
- Patient Recruitment Timeline: Quoin aims to complete patient recruitment for its Phase 3 study by the end of 2026 and potentially file for FDA approval in 2027, which, if successful, would make it the first approved treatment for Netherton Syndrome, addressing a critical market need.
- Clinical Data Submission: The company plans to submit clinical data from ongoing Phase 2 and pediatric studies based on FDA feedback and intends to meet with the FDA before initiating the pivotal Phase 3 program to ensure alignment on the study design.
See More
